This content is machine translated SGLT2i for heart failure HF prevalence in diabetes patients is underestimated in everyday clinical practice SGLT2 inhibitors can significantly reduce the risk of hospitalization for heart failure (HF) and death from cardiovascular causes in patients with diabetes and HF. However, the diagnosis of HF is…
View Post 4 min This content is machine translated Type 2 diabetes ESC recommendations for reducing cardiovascular risk Patients with type 2 diabetes have a greatly increased risk of developing cardiovascular disease compared to healthy people in the same age group. The current guidelines published in the European…
View Post 5 min This content is machine translated Renal insufficiency in general practice Improve early detection and inhibit progression The most common causes of chronic kidney disease (CKD) include diabetes and hypertension. Regular screening is recommended if there is an increased risk of CKD. In addition to the eGFR,…
View Post 9 min This content is machine translated Update ESC Guidelines 2023 Detailed recommendations for cardiovascular diseases in diabetes The updated guideline recommends important innovations in the areas of screening, cardiovascular risk assessment in diabetes mellitus and aspects of evidence-based cardiovascular risk reduction in type 2 diabetes patients with…
View Post 4 min This content is machine translated ESC guidelines on heart failure These are the new recommendations Numerous studies published in the last two years made it necessary to update the 2021 ESC Heart Failure Guidelines. In particular, this refers to new studies on SGLT2 inhibitors in…
View Post 4 min This content is machine translated Rare vasculitides - polyarteritis nodosa (PAN) Hepatitis B has lost in diagnostics, proteinuria has won Polyarteritis Nodosa (PAN) is a vasculitis of medium and small vessels. The incidence is estimated at 1.6 to 1.9 cases per million inhabitants per year, which is probably one reason…
View Post 6 min This content is machine translated ESC Guideline 2023 on ACS What is new in antithrombotic therapy? The clinical presentation of acute coronary syndrome (ACS) is broad and ranges from asymptomatic to persistent chest discomfort to cardiac arrest, electrical/hemodynamic instability and cardiogenic shock. The European Society of…
View Post 7 min This content is machine translated Aspirin-free strategy after PCI No reduction in bleeding (STOPDAPT-3 study) No ESC Congress without new studies on antithrombotic therapy after percutaneous coronary intervention. Recently, monotherapy with a P2Y12 blocker has increasingly emerged as an attractive alternative to dual antiplatelet therapy…
View Post 3 min This content is machine translated Rare diseases Brugada syndrome Brugada syndrome is an ion channel disorder in which there is an electrical disturbance of heart function without recognizable structural heart disease. This genetic heart rhythm disorder is associated with…
View Post 4 min This content is machine translated ESC update for SGLT-2-i Heart failure patients benefit regardless of LVEF The results of cardiovascular endpoint studies showing that dapagliflozin and empagliflozin significantly improve outcomes in HFpEF and HFmrEF have prompted the European Society of Cardiology (ESC) to adapt its recommendations.…
View Post 8 min This content is machine translated Percutaneous coronary intervention (PCI) Benefits of complete revascularization in elderly patients The benefit of complete revascularization in older patients (≥75 years) with myocardial infarction and multivessel disease is still unclear. At the ESC Congress, however, the results of the FIRE study…
